In a phase II trial of metastatic melanoma patients who had progressed on checkpoint blockade, the combination of sotigalimumab (APX005M CD40 agonist antibody) and nivolumab was able to induce long-lasting clinical tumor response in a subset of patients (175). Here, CD40 is linked to neoplasm.